AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Fortive, you generally need to believe in its ability to grow earnings from a higher mix of recurring, software-heavy revenues while managing trade, healthcare and government spending headwinds. The latest dividend increase and better than expected Q2 results support that earnings driven narrative, but do not remove the near term risk that public sector budget constraints and healthcare reimbursement pressures could still weigh on parts of the portfolio if end markets stay uneven.
The most relevant recent announcement here is Fortive’s Q2 2026 earnings, where revenue rose to US$1,096.8 million with improved adjusted EBITDA and EPS versus last year and analyst expectations. Combined with roughly US$2,000.0 million of share repurchases over the past four quarters, this creates a backdrop where the higher dividend looks supported by recent performance, even as investors continue to watch how trade policy, government spending, and healthcare demand shape the next leg of earnings.
But while the dividend hike and Q2 beat look reassuring, investors should still be aware of how ongoing tariff and trade uncertainty could...
Read the full narrative on Fortive (it's free!)
Fortive's narrative projects $4.7 billion revenue and $773.3 million earnings by 2029.
Uncover how Fortive's forecasts yield a $64.36 fair value, a 7% upside to its current price.
Some of the lowest ranked analysts tell a much more cautious story, assuming revenue around US$4.7 billion and earnings near US$741 million by 2029, so it is worth comparing those expectations with Fortive’s recent dividend increase and Q2 surprise to see whether this new information might eventually shift such a pessimistic view.
Explore 5 other fair value estimates on Fortive - why the stock might be worth just $64.36!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com